ACTU · Actuate Therapeutics, Inc.
$1.18
-0.08 (-6.35%)
At close · Jul 24
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the above matters, we have concluded that there is substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$28.23M
Shares
23.93M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Daniel M. Schmitt | CEO | $2,166,522 |
| Andrew P. Mazar | COO | $1,419,569 |
| Paul Lytle | CFO | $1,006,361 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Daniel M. Schmitt | CEO | $5,578,616 |
| Paul Lytle | CFO | $1,896,096 |
| Andrew P. Mazar | COO | $675,000 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Andrew P. Mazar | COO | $666,112 |
| Daniel M. Schmitt | CEO | $520,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Martin H. Huber, MD | Class III director | Appointed | 2026-05-06 |
Key facts
CIK
1652935
CUSIP
005083100
13F (30d)
12 filings
12 filers
Visit website
Investor relations